PD-1 and CTLA-4 blockade are most effective in patients that already have tumors with a substantial immune infiltrate rich in CD8+ T cells13, limiting the applicability of PD-1 and CTLA-4 blockade across many cancer types. Here, CTLA4 is linked to cancer.